Screening

What are aneuploidies and should I consider NIPT to screen for them during pregnancy?

Aneuploidies are chromosome conditions where a baby has too many or too few chromosomes. NIPT is a highly accurate, non-invasive blood test that screens for the most common aneuploidies from 9-10 weeks of pregnancy.

Published Updated Reading time 7 min By Jeen Health editorial team
Pregnant woman reviewing screening test results with midwife

Aneuploidies are chromosome conditions where a baby has too many or too few chromosomes. The most common is Down’s syndrome (also called trisomy 21), where the baby has three copies of chromosome 21 instead of the usual two. These conditions can affect a baby’s development and health, and many parents want to know whether their pregnancy is affected.

Non-invasive prenatal testing (NIPT) is a blood test that screens for the most common aneuploidies from as early as 9 weeks of pregnancy. It analyses small fragments of DNA from the placenta that circulate in your blood. NIPT has the highest detection rate and lowest false-positive rate among aneuploidy screening methods, but it’s not perfect - false-positive results can occur. This article explains what aneuploidies are, how NIPT works, and whether screening is right for you.

What are aneuploidies?

Most people have 46 chromosomes arranged in 23 pairs - 22 numbered pairs plus a pair of sex chromosomes (XX or XY). Aneuploidies happen when a baby has an extra or missing chromosome. The three most common aneuploidies screened for in pregnancy are:

Other aneuploidies involve the sex chromosomes (such as Turner syndrome or Klinefelter syndrome) or rarer numbered chromosomes. Some NIPT panels screen for these as well.

Aneuploidies usually happen by chance when the egg or sperm forms - they’re not typically inherited. The chance of an aneuploidy increases with maternal age, but they can occur in any pregnancy.

How does NIPT work?

During pregnancy, small fragments of DNA from the placenta enter your bloodstream. NIPT analyses this cell-free DNA (called cffDNA) in a sample of your blood to estimate the chance that the pregnancy is affected by an aneuploidy.

The test measures the amount of DNA from each chromosome. If there’s an extra copy of chromosome 21 in the baby, for example, the lab will detect slightly more chromosome 21 DNA in your blood sample than expected.

NIPT is available from 9 or 10 weeks of pregnancy, depending on the specific test. It requires only a blood sample from your arm - no needles near the baby - so it carries no risk of miscarriage. Results are usually ready within a few days to 10 working days, depending on the laboratory and panel.

What NIPT can and cannot tell you

NIPT is a screening test, not a diagnostic test. A high-risk result means the chance of the condition is increased, but it doesn’t confirm the baby definitely has it. Similarly, a low-risk result means the chance is very low, but not zero. If NIPT returns a high-risk result, you’ll be offered genetic counselling and the option of a diagnostic test - either chorionic villus sampling (CVS) or amniocentesis - to confirm the result.

NIPT performs very well for detecting the common autosomal aneuploidies (trisomy 21, 18, and 13). For Down’s syndrome, NIPT has a detection rate above 99% and a very low false-positive rate. However, false-positive results can occur - for example, due to confined placental mosaicism (where the placenta has an aneuploidy but the baby does not) or other biological factors.

NIPT does not screen for all pregnancy complications or birth defects. A 12- or 13-week ultrasound scan is still recommended alongside NIPT, as it can identify structural abnormalities - such as heart defects or neural tube defects - that NIPT cannot detect.

Should you have NIPT?

In England, the NHS offers combined first-trimester screening (a blood test at 10-14 weeks and a nuchal translucency ultrasound at 11-14 weeks) to all pregnant people. If the result shows a higher chance of one of the conditions, the NHS offers NIPT as one of your options, alongside a diagnostic test (CVS or amniocentesis) or no further tests. In Scotland, Wales, and Northern Ireland, policies may differ.

Private NIPT is widely available and does not require a GP referral, so you can choose it as your first screening test if you prefer. Whether to have NIPT is a personal decision. Consider:

There is no right or wrong choice. A midwife or genetic counsellor can discuss your options without pressure, helping you decide what fits your values and circumstances.

What happens if NIPT shows a high-risk result?

A high-risk NIPT result does not mean your baby definitely has the condition. You’ll be offered:

If the diagnostic test confirms an aneuploidy, you’ll have time to discuss what this means for your baby and family, plan for specialist care, or consider all your options, including continuing or ending the pregnancy. Support is available whatever you decide.

What you can do at Jeen

Jeen offers several NIPT options to suit different needs and timelines, all with a midwife consultation included before you take the test (a £50 consultation fee applies if you speak with the midwife but testing does not go ahead):

The NHS newborn blood-spot screen (heel-prick test) checks for a small, fixed set of serious conditions after birth. NIPT, by contrast, screens during pregnancy for chromosomal conditions, giving you information earlier and more time to prepare or make decisions. All Jeen NIPT tests use a blood sample taken from your arm. Blood collection is not included in the test price: you can arrange your own blood draw with no extra Jeen charge (check whether the clinic or surgery charges its own fee), or pay extra for a partner collection point (+£40) or a home-nurse visit (+£65). Each test includes a midwife consultation to help you understand your options and results.

Sources & further reading

  1. PubMed Poulton A, Hui L. Noninvasive prenatal testing: an overview. Aust Prescr. 2025;48(2):47-53. DOI: 10.18773/austprescr.2025.019. Accessed 22 September 2026.
  2. PubMed Gadsbøll K, Vogel I, et al. Combined first-trimester screening and invasive diagnostics for atypical chromosomal aberrations: Danish nationwide study. Ultrasound Obstet Gynecol. 2024;64(4):470-479. DOI: 10.1002/uog.27667. Accessed 22 September 2026.
  3. PubMed Konya M, Czimbalmos A, et al. Genome-Wide, Non-Invasive Prenatal Testing for rare chromosomal abnormalities: A systematic review and meta-analysis. PLoS One. 2024;19(11):e0308008. DOI: 10.1371/journal.pone.0308008. Accessed 22 September 2026.
niptaneuploidydown-syndromeprenatal-screeningtrisomypregnancy